SCHEMBL14646172

SCHEMBL14646172

O=C(O)CCc1cc(-c2ccc(-c3ccc(C(=O)O)s3)s2)sc1-c1ccc(-c2sc(-c3ccc(-c4ccc(C(=O)O)s4)s3)cc2CCC(=O)O)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
HPGDS O60760 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
PTGER1 P34995 1/20 0.39
PTGER4 P35408 1/20 0.39
PTGER3 P43115 1/20 0.39
PTGER2 P43116 1/20 0.39
RPS6KB2 Q9UBS0 1/20 0.38
ALDH1A1 P00352 4/20 0.37
HPGD P15428 3/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TDP1 Q9NUW8 1/20 0.35
LMNA P02545 1/20 0.35
PRNP P04156 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14645266 1.00 MEN1 (0.40) MEN1POLBRAB9AKMT2AHPGDS
SCHEMBL14646265 0.91 PTGER1 (0.39) POLBHPGDSPTGER1PTGER4PTGER3
SCHEMBL15695308 0.90 ALDH1A1 (0.46) MEN1POLBRAB9AKMT2AALDH1A1
SCHEMBL14646234 0.90 POLB (0.45) MEN1POLBRAB9AKMT2AHPGDS
SCHEMBL14645302 0.87 POLB (0.41) MEN1POLBRAB9AKMT2AHPGDS
SCHEMBL14645501 0.87 POLB (0.41) MEN1POLBRAB9AKMT2AHPGDS
SCHEMBL9976545 0.86 ALDH1A1 (0.40) MEN1POLBRAB9AKMT2AHPGDS
SCHEMBL14645296 0.85 POLB (0.41) MEN1POLBRAB9AKMT2AHPGDS
SCHEMBL14646273 0.85 POLB (0.41) MEN1POLBRAB9AKMT2AHPGDS
SCHEMBL14646131 0.85 POLB (0.41) MEN1POLBRAB9AKMT2AHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 US disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 US disclosed
WO-2013036196-A1 NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING BIOCHROMIX AB (SE) 2013-03-14 WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY PRNP, TBCA, HSPA5 MEN1 2047/4885POLB 1618/4885RAB9A 1733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.